Boomfish Wealth Group LLC Boosts Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Boomfish Wealth Group LLC increased its stake in Thermo Fisher Scientific Inc. by 30.5% in the 2nd quarter, resulting in ownership of 6,026 shares worth approximately $2.44 million.
• Thermo Fisher's stock is currently valued at $536.21 with a market cap of $202.48 billion, and it recently reported earnings of $5.36 EPS, exceeding estimates.
• Recent transactions by company insiders included the sale of shares by the CAO and CEO, collectively affecting ownership by a small percentage while still holding significant value.

Boomfish Wealth Group LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 30.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,026 shares of the medical research company's stock after buying an additional 1,407 shares during the period. Boomfish Wealth Group LLC's holdings in Thermo Fisher Scientific were worth $2,443,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in TMO. Brighton Jones LLC increased its stake in Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock worth $2,293,000 after buying an additional 988 shares during the period. Revolve Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares during the period. Capital Investment Advisors LLC increased its stake in Thermo Fisher Scientific by 2.4% in the 1st quarter. Capital Investment Advisors LLC now owns 1,367 shares of the medical research company's stock worth $680,000 after buying an additional 32 shares during the period. Daymark Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 31.5% in the 1st quarter. Daymark Wealth Partners LLC now owns 776 shares of the medical research company's stock worth $386,000 after buying an additional 186 shares during the period. Finally, Farther Finance Advisors LLC increased its position in Thermo Fisher Scientific by 27.9% during the 1st quarter. Farther Finance Advisors LLC now owns 5,048 shares of the medical research company's stock valued at $2,438,000 after purchasing an additional 1,100 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Down 0.5%

NYSE:TMO opened at $536.21 on Thursday. The company has a market cap of $202.48 billion, a PE ratio of 31.01, a P/E/G ratio of 2.93 and a beta of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The company's 50 day moving average is $486.09 and its two-hundred day moving average is $448.21.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares of the company's stock, valued at approximately $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,066 shares of company stock valued at $14,182,963. Insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Weiss Ratings reissued a "hold (c-)" rating on shares of Thermo Fisher Scientific in a research report on Saturday, September 27th. Redburn Partners set a $580.00 target price on shares of Thermo Fisher Scientific in a research report on Wednesday. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, October 4th. Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the company an "outperform" rating in a research report on Tuesday, September 2nd. Finally, Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Fifteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $590.60.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.